PropThink: QCOR Beat Down To Reverse; Synacthen Toxic To Infants, Not A Real Threat
By David Moskowitz
Shares of Questcor Pharmaceuticals (NASDAQ:QCOR) are under pressure Friday, down 10% in morning trading on news that unknown drug company Cerium Pharmaceuticals has received Orphan Drug status from the FDA for its synthetic ACTH product, Synacthen Depot for Infantile Spasms (IS). Questcor's H.P. Acthar Gel (Acthar) is a naturally-produced ACTH product and is indicated for IS among other conditions, therefore, investors are sensitive to this issue on the belief that Synacthen Depot could represent "generic" competition to Acthar. This news today is a significant buying opportunity for several reasons: 1) Synacthen Depot is known to contain benzyl alcohol which has been implicated in infant toxicity (various articles here). As a result, FDA approval for a product containing this ingredient in infants is highly unlikely. 2) H.P. Acthar Gel already has Orphan Drug status in IS and this exclusivity expires in 2017. The chance that FDA would overrule Acthar's Orphan Drug exclusivity is very slim, so even if Synacthen Depot was an actual threat, gaining market approval in the U.S. before 2017 is unlikely. 3) IS is only a small portion of Acthar sales anyway; other indications are driving growth. Because "off-label" use is so heavily scrutinized with Acthar, Synacthen would have trouble getting used anywhere besides its FDA approved indication, if approved. 4) Who is Cerium Pharmaceuticals? See link here for the location of this company. (Perhaps someone's home office in Maryland?) We see little to no threat from Synacthen Depot; investors can step into QCOR and take advantage of today's weakness. We wouldn't be surprised to see the stock regain all of its losses from this morning's downturn.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us on Twitter or visit us at http://www.propthink.com.
You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. PropThink was not compensated to publish this article. Our full disclaimer is available at http://www.propthink.com/disclaimer.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: PropThink via Thomson Reuters ONE
- Housing, jobs data weaken, but overall economic picture still upbeat
- Putin critic Khodorkovsky free after pardon, heads for Germany |
- Target cyber breach hits 40 million payment cards at holiday peak |
- Pizza outlet attacked as India, U.S. fail to cool diplomat row |
- New York Mayor-elect's reputation for lateness parodied on Twitter